# OnCo record ibi3009 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ibi3009/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ibi3009" ;
  schema:name "IBI3009"@en ;
  schema:description "IBI3009 is an experimental antibody-drug conjugate for small cell lung cancer, aimed at the protein DLL3. Innovent Biologics licensed it to Roche in January 2025, and it is in a first phase 1 trial."@en ;
  schema:url <https://onco.cc/drugs/ibi3009/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.drugdiscoveryonline.com/doc/innovent-enters-into-exclusive-global-license-roche-for-novel-dll-antibody-drug-conjugate-0001>, <https://clinicaltrials.gov/study/NCT06613009> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "deal-asset" ;
  onco:modality "Antibody-drug conjugate (DLL3, topoisomerase I inhibitor payload)" ;
  onco:cancers <https://onco.cc/cancers/sclc/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/dll3/> ;
  onco:companies <https://onco.cc/companies/innovent/>, <https://onco.cc/companies/roche-genentech/> ;
  onco:trials <https://onco.cc/trials/nct06613009/> .